<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7FD49690-1A72-4C79-B22E-7CFC3594C685"><gtr:id>7FD49690-1A72-4C79-B22E-7CFC3594C685</gtr:id><gtr:name>Pathfinder Bio</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Chemistry</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7FD49690-1A72-4C79-B22E-7CFC3594C685"><gtr:id>7FD49690-1A72-4C79-B22E-7CFC3594C685</gtr:id><gtr:name>Pathfinder Bio</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B9A0B36E-D18D-40A3-AF66-0918CDD0B776"><gtr:id>B9A0B36E-D18D-40A3-AF66-0918CDD0B776</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Nigel</gtr:otherNames><gtr:surname>Barlow</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FI007946%2F1"><gtr:id>97BCDAB0-CFF1-4C59-93FB-37CD8C88DFA6</gtr:id><gtr:title>The 'safety catch' on the trigger for formation of the membrane attack complex - a structural analysis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/I007946/1</gtr:grantReference><gtr:abstractText>The job of the body's immune system is to detect and to then destroy invading cells, such as bacteria, which threaten our health and can ultimately kill us. This proposal is concerned with potent weapons employed by the body to destroy bacterial cells, but which sometimes go astray and damage our own tissues. The ability of components within human blood to burst open foreign cells was first recognised almost a century ago and represented one of the great early discoveries of immunology. Today, the eleven proteins involved (called C1, C2, C3 etc. up to C9 and factors B and D) have been thoroughly characterised. The sequence in which they act (roughly starting with C1 and culminating with C9) is also well established. The grand finale is the self-assembly on cell membranes of a ring of C9 proteins that punches a hole (or pore) right through the membrane. Many thousands of such pores can form on a cell resulting in leakage of its contents, an influx of water, swelling and rupture ('cytolysis'). It is clearly vital to minimise the number of such pores that form on our own cells. Unfortunately this does not always happen. Many diseases are associated with failure to control MAC formation on human cells and there is a lot of interest in developing inhibitors of the MAC as potentially powerful drugs. One way in the body controls MAC assembly is by ensuring that formation of the pore itself can occur only after C6 and C7 have assembled on C5b to form a 'pre-lytic' complex. The key point is that C5b is not normally present in the blood in substantial quantities. Its creation (by conversion from inactive C5) is triggered by detection of bacteria or other hazardous particles. In this proposal we want to take a very close look at the role played by C5b in nucleating MAC formation. In particular we will focus our efforts on the proteins C7 and C6. We suspect that C7, like C8 and C9, contains the molecular equivalent of a flick-knife fitted with a safety catch. Release of the safety catch results in the flipping out of a blade like structure that effectively cuts through the membrane. One proposal is that C5b is necessary for release of the safety catch in C7 and we wish to investigate whether this is true and if it is, then we want to find out precisely how this comes about. This will involve taking a very detailed look at the structure of the safety catch and its mode of interaction. In our model, the safety catch consists of a swinging arm of C7 that interacts with itself to maintain MACPF in a state of latency, or with C5b to release the MACPF. We propose to dissect the arm, into its component domains and study their structures, how flexibly they are attached to one another and how the arm is disposed relative to the MACPF domain in C7. These insights will be useful in the future design of small molecules designed to prevent the safety catch from releasing. Such molecules would be the starting points for therapeutic compounds in clinical settings where dangerous levels of the MAC form on human cell surfaces.</gtr:abstractText><gtr:technicalSummary>The self-assembly of a membrane-penetrating pore (the membrane-attack complex or MAC) from its soluble plasma protein components C5b, C6, C7, C8 and C9 is the best known, least well understood, and most destructive outcome of the complement system. Deficiencies increase susceptibility to bacterial infection; nonetheless, MAC assembly is a candidate for therapeutic intervention where need to modulate inflammation outweighs accompanying elevated risks of infection. The sequence of MAC-forming events was established &amp;gt; 25 years ago, while more recently structure determination of the C8alpha MACPF domain revealed the molecular 'flick knife' potential of this domain-type. But molecular mechanisms initiating MAC assembly are poorly understood. We shall interrogate a hypothetical mechanism for assembly of the C5b.C6.C7 (C5b67) complex that associates with membranes and recruits bilayer-penetrating C8 and C9 components. We will focus on a putative molecular 'safety catch'. This consists of an array of C-terminal modules in C7 that, we think, prevents the C7 MACPF domain undergoing the critical and irreversible transition to a membrane-associative form. In our model, release of the safety catch is contingent upon relocation of C-terminal modules from MACPF to a binding site on C5b (in the context of C5b67 complex) thus ensuring MAC assembly can occur only following activation of C5 to C5b. We will test key predictions of our model regarding the 3D solution structure and flexibility of the C-terminus of C7 and its relationship with the MACPF domain. Results will be extrapolated to the close homologue, C6. Chemical cross-linking and small-angle X-ray scattering will guide modelling of C7 and C6 substructures and their complexes with C5b. This data will illuminate the steps that couple complement amplification with the lytic terminal pathway. It will provide sound foundations upon which to select the optimal target for therapeutic reagents.</gtr:technicalSummary><gtr:potentialImpactText>We will continue to work with the Edinburgh University Press Office and the University's technology transfer company (ERI Ltd) to ensure the results of our research on the membrane attack complex reach both the public and relevant commercial audiences. Where appropriate we will file for patent protection as we have done with our work on expression of factor H. Furthermore, the results of the proposed research may help build the foundations needed to establish the C5b-C6/C7 interaction as a target for the powerful array of in-house ligand discovery platforms (ultrahigh-throughput screening, peptide hit morphing etc.) housed within our new Centre for Translational and Chemical Biology. There is a very clear unmet need for therapeutic interventions that limit complement action. As was illustrated in Fig. 1 (Part 1a) the last proteolytic step in the amplification/activation phase of the pathway is the cleavage of C5 into the anaphylatoxin C5a and the MAC-initiating C5b fragment. Binding of nascent C5b (C5b*) to C6 and then to C7 initiates self-assembly of the MAC, which has the structure C5b1C61C71C81C9n, where n is between about 10 and 16. It is important to note that all the activation products responsible for stimulation of potentially beneficial cellular immune responses are already generated before MAC assembly is initiated. Unregulated or inappropriate complement activation is a, if not the, major contributor to a variety of pathologies including age-related macular degeneration. Inhibitors that block specifically the terminal pathway are advantageous since they avoid compromise of the more beneficial complement functions. Furthermore, long-term MAC inhibition as might be needed in chronic conditions may have only mild side-effects, based on the observation that the consequences of genetic deficiencies in MAC proteins are manageable. Finally, blocking incorporation of C6 or C7 into the nascent MAC is the most desirable goal of all because C5b and C5b-6 do not damage the plasma membrane, whereas even the C5b67 intermediate can induce inflammatory responses.</gtr:potentialImpactText><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-08-15</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>377066</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pathfinder Bio</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Ocular therapeutics</gtr:description><gtr:id>718F4F3B-C928-4093-9297-18C4E3B6220D</gtr:id><gtr:impact>None yet - research activities commencing in March 2016</gtr:impact><gtr:outcomeId>56dd599d0e4058.73259265-1</gtr:outcomeId><gtr:partnerContribution>James McLaughlin has led in company formation and raising seed funding.</gtr:partnerContribution><gtr:piContribution>I will be a Scientific Founder of new ocular therapeutics company, Gemini Therapeutics. Focus is on complement and factor H. I have helped to raise seed funding from VCs. Our research team is contributing expertise in experimental design and data analysis and interpretation, preparation and testing of complement proteins for PK studies, advice and consultancies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk in International Complement Workshop, Rio de Janeiro</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>34897497-A77E-4613-86B4-D63176579FA3</gtr:id><gtr:impact>Talk sparked many questions and much discussion

initiated new collaborations</gtr:impact><gtr:outcomeId>545a7681523fc0.06195370</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://icwrio2014.com/wp-content/uploads/2014/06/icw_programafinal01082014.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk at Aegean Meeting on Biocompatible surfaces</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>955762AB-2BA9-44C2-88B9-0694B0528FA8</gtr:id><gtr:impact>talk sparked interest and discussions

new collaborations</gtr:impact><gtr:outcomeId>545a77964d8094.70212174</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.aegeanconferences.org/conferenceFront.do?method=openMenu&amp;tempIdx=3</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISSF</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>97A8E4B0-8D85-47C6-A77B-98F7B73D4F1D</gtr:id><gtr:outcomeId>G8LWZvfkF4P</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>420365</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Device Coatings (H-Guard) Phase 2</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Scottish Enterprise</gtr:fundingOrg><gtr:fundingRef>PS7305CA45</gtr:fundingRef><gtr:id>42EE62E7-6C53-4B5B-96A6-C4439C650BF1</gtr:id><gtr:outcomeId>58bed144de4195.84583608</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Follo-on-funding - unlocking potential of FH</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/L024403/1</gtr:fundingRef><gtr:id>ABBA71E0-B9FE-42A5-8A90-6C7CE3860B84</gtr:id><gtr:outcomeId>545a7330c29369.69124601</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sparking Impact</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>18A6F9A5-1E04-45BF-B4EF-AFA9FC12DD53</gtr:id><gtr:outcomeId>JDvjQdv9QDQ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE studentship with Ingenza</gtr:description><gtr:end>2017-08-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:fundingRef>BB/K011774/1</gtr:fundingRef><gtr:id>EC6D8AC4-7F75-44D5-8CB6-1531AA47DF2C</gtr:id><gtr:outcomeId>545a72ab486fc9.39597449</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>The complement system can very rapidly become activated on any blood-exposed surface including the surfaces of our own cells and tissues. The ultimate consequence of complement activation is the formation of membrane-attack complexes that penetrate cellular membranes and cause cells to lyse or burst. The complement system is said to be triggered - able to respond almost instantly to an invading bacterium or virus. This provides a highly effective first line of defence but is potentially dangerous. Consequently, there are safety catches tasked with preventing inappropriate activation. These can fail leading to disease. We set out to discover precisely how safety catches work with a view to designing therapeutic strategies for complement suppression.

In this work we focused on the main, soluble, safety catch on the trigger of complement activation, a protein called factor H. Note that our original proposal was focused on a more downstream safety catch in the pathway.

The most important and potentially game-changing finding of our work was that factor H can switch between a latent or quiescent conformation and an activated conformation that has enhanced regulatory potential. The quiescent form circulates in blood. It is able to control fluid-phase regulation of complement but is unable to keep surface-based complement activation in check. The enhanced-activity conformation, on the other hand, is induced by sugars that are specific to host surfaces. In this way host surfaces (as well as bacteria that mimic them) are protected from complement-mediated injury. While there are some aspects of this hypothesis that require confirmation we think that we have discovered the molecular mechanism underpinning the ability of complement to distinguish between self and non-self.</gtr:description><gtr:exploitationPathways>The bacterial protein that anchors and stabilises the activated conformation of the complement regulator factor H has potential application in biocompatible surfaces, diagnostics and therapeutics. We have filed a priority application based on these potential uses.</gtr:exploitationPathways><gtr:id>28B41091-6FFE-46CD-86A6-879DBAF24669</gtr:id><gtr:outcomeId>545b4da74d7066.97323691</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors><gtr:url>http://www.research-innovation.ed.ac.uk/Opportunities/surface-coatings-for-medical-devices.aspx#page=overview</gtr:url></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4E73A1B3-C509-4B67-82B0-0B91706E2514</gtr:id><gtr:title>Recruitment of Factor H as a Novel Complement Evasion Strategy for Blood-Stage Plasmodium falciparum Infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/149a3d3325939f1ef5421e305fb74b4b"><gtr:id>149a3d3325939f1ef5421e305fb74b4b</gtr:id><gtr:otherNames>Kennedy AT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56dd53f106bfd9.34787489</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9765BE84-1239-436E-A332-DB0DB3EA90C3</gtr:id><gtr:title>New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties.</gtr:title><gtr:parentPublicationTitle>Immunobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9df68783e1572a51c545af6c8799add1"><gtr:id>9df68783e1572a51c545af6c8799add1</gtr:id><gtr:otherNames>Qu H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0171-2985</gtr:issn><gtr:outcomeId>pm_16512_22_22795972</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FFF2B90-685E-4B24-8E25-7313843FD5D2</gtr:id><gtr:title>Solution structure of CCP modules 10-12 illuminates functional architecture of the complement regulator, factor H.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c54395becaa59e5d097298e33fa415f"><gtr:id>0c54395becaa59e5d097298e33fa415f</gtr:id><gtr:otherNames>Makou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>pm_16512_22_23017427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CAF7596-FFAB-464C-98B7-ADD45996EAAF</gtr:id><gtr:title>Functional anatomy of complement factor H.</gtr:title><gtr:parentPublicationTitle>Biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c54395becaa59e5d097298e33fa415f"><gtr:id>0c54395becaa59e5d097298e33fa415f</gtr:id><gtr:otherNames>Makou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-2960</gtr:issn><gtr:outcomeId>pm_16512_22_23701234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC987616-F2C0-4470-99D2-66F40BF023EC</gtr:id><gtr:title>Quantitative cross-linking/mass spectrometry reveals subtle protein conformational changes.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbfbba64e0bed5a5bd0e165199be7334"><gtr:id>bbfbba64e0bed5a5bd0e165199be7334</gtr:id><gtr:otherNames>Chen Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>5a355c48b3f378.02120828</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46B59656-55CB-4610-916E-AFAB68165002</gtr:id><gtr:title>Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d83e3adf41c8a714a9ffeb3269f4d6b7"><gtr:id>d83e3adf41c8a714a9ffeb3269f4d6b7</gtr:id><gtr:otherNames>Weiss GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>56dd557040b322.21616774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4A06029-5ACD-47F4-8B6E-D86DD7835D9B</gtr:id><gtr:title>Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7075d878e784982bac9c9c3349a7bb4"><gtr:id>d7075d878e784982bac9c9c3349a7bb4</gtr:id><gtr:otherNames>Wong EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>545a6dbeeea4b0.55107880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>792FA2EC-E586-4F45-B7D7-B5D8760D4E6D</gtr:id><gtr:title>Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6e70f03c85d809c965975b91965c1bd6"><gtr:id>6e70f03c85d809c965975b91965c1bd6</gtr:id><gtr:otherNames>Harder MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56dd54b4e761a0.29042629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7182941B-0062-40D5-84BB-2AA69A1500F7</gtr:id><gtr:title>Creating functional sophistication from simple protein building blocks, exemplified by factor H and the regulators of complement activation.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c54395becaa59e5d097298e33fa415f"><gtr:id>0c54395becaa59e5d097298e33fa415f</gtr:id><gtr:otherNames>Makou E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>56dd5570678536.46532034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>395D1566-2B3D-4BFA-B507-92BFFA8BD56D</gtr:id><gtr:title>Complement Evasion Mediated by Enhancement of Captured Factor H: Implications for Protection of Self-Surfaces from Complement.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d51ddea33c74777c1686c55b26873b9e"><gtr:id>d51ddea33c74777c1686c55b26873b9e</gtr:id><gtr:otherNames>Herbert AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56dd5504d2d2a5.44727582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E852A6B-27F8-47E7-9395-965F11932674</gtr:id><gtr:title>Decoding the components of dynamics in three-domain proteins.</gtr:title><gtr:parentPublicationTitle>Journal of computational chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a19d7fa3fc173735fb7d3d3ab58f14ab"><gtr:id>a19d7fa3fc173735fb7d3d3ab58f14ab</gtr:id><gtr:otherNames>Maciejewski M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0192-8651</gtr:issn><gtr:outcomeId>pm_16512_22_24323885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01573F5A-3DA3-4C87-9E6C-A508D6E46824</gtr:id><gtr:title>Structure of Complement C3(H2O) Revealed By Quantitative Cross-Linking/Mass Spectrometry And Modeling.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/44cc33ecf634ebc47e50139ceb78614c"><gtr:id>44cc33ecf634ebc47e50139ceb78614c</gtr:id><gtr:otherNames>Chen ZA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn><gtr:outcomeId>585d3a0fb3d7c2.09792804</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/I007946/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>